Literature DB >> 34001231

Clinical and demographic pattern of chronic granulomatous disease (CGD) from a multicenter perspective: Malaysia's experience over 26 years.

Lokman Mohd Noh1,2, Amir Hamzah Abdul Latiff3, Intan Hakimah Ismail4, Rahim Md Noah5, Asrul Abdul Wahab6, Intan Juliana Abd Hamid7, Adiratna Mat Ripen8, Nasuruddin B Abdullah9,10, Kamarul Azhar Razali11, Norzila Zainudin12,13, Florence Bakon14, Long Juan Kok15, Adli Ali16, Bilkis Banu SAbd Aziz16, Hasniah Abdul Latif16, Siti Mardhiana Mohamad17, Zarina Thasneem Zainudeen7, Ilie Fadzilah Hashim7, Iean Hamzah Sendut18,19, Thiyagar Nadarajaw20, Faizah Mohamed Jamil21, David C E Ng22,15, Mohd Azri Zainal Abidin4.   

Abstract

BACKGROUND: A retrospective review of clinical manifestations and demographic pattern of patients diagnosed as chronic granulomatous disease (CGD) from 7 hospitals in Malaysia. An analysis of the available database would establish clinical characteristics, diagnoses and outcome including microbiologic pattern. Studying the demography allows us to document the occurrence of CGD amongst multiethnic groups and its geographical distribution for Malaysia.
METHODS: Data from the Malaysia Primary Immunodeficiency Network (MyPIN) with cases of CGD diagnosed from 1991 until 2016 were collated and analysed.
RESULTS: Twenty patients were diagnosed as CGD. Males (N = 13, 65%) outnumber females (N = 7, 35%). CGD is commonest amongst the Malays (65%) followed by the Chinese (15.0%), Indians (10.0%) and natives of Borneo (10.0%), reflecting the ethnic composition of the country. The mean age of diagnosis was 3.7 years. There was a positive family history in 40% of the cases. Abscess was the main presenting feature in 16 patients (80%) with one involving the brain. Pneumonia occurred in 10 (50%) and one with complicated bronchiectasis. Catalase-positive bacteria were the most commonly isolated pathogen with Chromobacterium violaceum predominating (N = 5, 25%) with consequent high mortality (N = 4, 80%). All CGD patients with C. violaceum infection displayed CD4 + (T helper cells) lymphopenia.
CONCLUSION: This study has shown CGD occurs in the major ethnic groups of Malaysia. To the best of our knowledge, this is the first and the largest series of chronic granulomatous disease in South East Asia which may be reflective of similar clinical pattern in the region. C. violaceum infection is associated with a higher mortality in CGD patients in Malaysia. All the CGD patients with C. violaceum infection in this patient series displayed CD4 + (T helper) lymphopenia. We recorded rare clinical manifestation of CGD viz. brain abscess and bronchiectasis.

Entities:  

Keywords:  CD4 + lymphopenia; Chromobacterium violaceum; Chronic granulomatous disease; Clinical; Demographic pattern; Malaysia

Year:  2021        PMID: 34001231     DOI: 10.1186/s13223-021-00551-4

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


  10 in total

1.  Chronic granulomatous disease.

Authors:  M Salaria; S Singh; L Kumar; U Datta; S Sehgal
Journal:  Indian Pediatr       Date:  1999-06       Impact factor: 1.411

2.  Evaluation of variable parameters in neutrophil function test using chemiluminescence assay.

Authors:  R M Noah; M R Jais; L M Noh
Journal:  Malays J Pathol       Date:  1994-12       Impact factor: 0.656

3.  Chronic granulomatous disease: a case report.

Authors:  J S Ma; P Y Chen; L S Fu; C S Chi; Y F Huang; C Y Lin; C C Shieh
Journal:  J Microbiol Immunol Infect       Date:  2000-06       Impact factor: 4.399

4.  Primary immunodeficiency diseases in Singapore--the last 11 years.

Authors:  D L Lim; B Y Thong; S Y Ho; L P C Shek; J Lou; K P Leong; H H Chng; B W Lee
Journal:  Singapore Med J       Date:  2003-11       Impact factor: 1.858

5.  Defining p47-phox deficient Chronic Granulomatous Disease in a Malay family.

Authors:  Harvindar Kaur Gill; Hemahwathy Chanthira Kumar; Jasbir Singh Dhaliwal; Farizawati Zabidi; Iean Hamzah Sendut; Rahim M Noah; Lokman Mohammad Noh; Amir Hamzah Abdul Latiff; Shahnaz Murad
Journal:  Asian Pac J Allergy Immunol       Date:  2012-12       Impact factor: 2.310

6.  Clinical-Epidemiological Pattern of Primary Immunodeficiencies in Malaysia 1987-2006: A 20 year experience in Four Malaysian Hospitals.

Authors:  L M Noh; B A Nasuruddin; A H Abdul Latiff; R M Noah; M R Kamarul Azahar; M Z Norzila; I Zulkifli; H K Gill; N I Nik Zainal; A W M Suhaimi; N Y Nik Khairulddin; H Maraina; H I Intan; I Mat; M Shahnaz; Azizi B H O
Journal:  Med J Malaysia       Date:  2013

7.  Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients.

Authors:  Jing Sun; Huijun Lai; Dong Shen; Pingping Wu; Jie Yang; Zhongwen Sun; Yundi Guo
Journal:  J Immunol Res       Date:  2017-12-20       Impact factor: 4.818

8.  Chromobacterium violaceum infection in chronic granulomatous disease: a case report and review of the literature.

Authors:  Zaal Meher-Homji; Rekha Pai Mangalore; Paul D R Johnson; Kyra Y L Chua
Journal:  JMM Case Rep       Date:  2017-01-31

9.  Chronic granulomatous disease: the European experience.

Authors:  J Merlijn van den Berg; Elsbeth van Koppen; Anders Ahlin; Bernd H Belohradsky; Ewa Bernatowska; Lucien Corbeel; Teresa Español; Alain Fischer; Magdalena Kurenko-Deptuch; Richard Mouy; Theoni Petropoulou; Joachim Roesler; Reinhard Seger; Marie-José Stasia; Niels H Valerius; Ron S Weening; Baruch Wolach; Dirk Roos; Taco W Kuijpers
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

10.  Systematic Review of Primary Immunodeficiency Diseases in Malaysia: 1979-2020.

Authors:  Intan Juliana Abd Hamid; Nur Adila Azman; Andrew R Gennery; Ernest Mangantig; Ilie Fadzilah Hashim; Zarina Thasneem Zainudeen
Journal:  Front Immunol       Date:  2020-08-26       Impact factor: 7.561

  10 in total
  1 in total

1.  The PID Principles of Care: Where Are We Now? A Global Status Report Based on the PID Life Index.

Authors:  Julia Nordin; Leire Solís; Johan Prévot; Nizar Mahlaoui; Helen Chapel; Silvia Sánchez-Ramón; Adli Ali; John W Seymour; Martine Pergent
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.